The FDA's regulatory decision regarding Summit Therapeutics' initial Biologics License Application for ivonescimab

I give a 50% probability that the FDA approves ivonescimab's initial application, primarily because its HARMONi trial missed the statistically significant overall-survival threshold (p=0.057) required for approval.

Summit Therapeutics has submitted a Biologics License Application (BLA) to the US FDA seeking approval for its drug ivonescimab, in combination with chemotherapy, for patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who were previously treated with a third-generation EGFR tyrosine kinase inhibitor (TKI). The application is based on data from the Phase III HARMONi trial. The FDA initially provided a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026. However, Summit recently submitted updated overall survival data to the FDA, which could potentially be considered a major amendment and trigger a three-month extension of the review period. Investors are closely watching to see if the FDA will approve this first-in-class PD-1/VEGF bispecific antibody.

This question resolves based on the first public announcement by Summit Therapeutics or the US FDA regarding the regulatory decision for the initial Biologics License Application (BLA) for ivonescimab in the specified EGFR-mutated NSCLC indication.

• "Approval (full or accelerated)" means the FDA grants marketing authorization for ivonescimab in the US (either full or accelerated approval).
• "Complete Response Letter (CRL) / Rejection" means the FDA issues a CRL indicating it will not approve the application in its present form.
• "Application withdrawn" means Summit officially withdraws the BLA prior to an approval or CRL decision.

Delays to the PDUFA date do not resolve the question; the question waits for the final decision.